WallStSmart

Definitive Healthcare Corp (DH)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 27131% more annual revenue ($65.77B vs $241.52M). MRK leads profitability with a 13.6% profit margin vs -57.5%. MRK earns a higher WallStSmart Score of 53/100 (C-).

DH

Hold

37

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 5/9Altman Z: -0.22

MRK

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 2.7Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHUndervalued (+84.5%)

Margin of Safety

+84.5%

Fair Value

$10.92

Current Price

$0.96

$9.96 discount

UndervaluedFair: $10.92Overvalued
MRKSignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$97.76

Current Price

$113.56

$15.80 premium

UndervaluedFair: $97.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DH1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

MRK4 strengths · Avg: 9.5/10
Market CapQuality
$277.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

DH4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$108.62M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-40.4%2/10

ROE of -40.4% — below average capital efficiency

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.432/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : DH

The strongest argument for DH centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.

Bear Case : DH

The primary concerns for DH are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

DH profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

DH carries more volatility with a beta of 1.34 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (53/100 vs 37/100). DH offers better value entry with a 84.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Definitive Healthcare Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Definitive Healthcare Corp (DH) is a premier provider of data and analytics solutions tailored for the healthcare sector, serving a wide array of clients including pharmaceutical firms, payers, and healthcare providers. By leveraging extensive datasets and real-time analytics, the company enhances operational performance and provides strategic insights that lead to improved patient outcomes. In an environment marked by increasing complexity and demand for healthcare analytics, Definitive Healthcare is strategically positioned to deliver innovative solutions that drive operational excellence and competitive advantage for its partners. With a commitment to enhancing healthcare delivery through data-driven insights, DH is at the forefront of transforming the healthcare landscape.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?